Global Anti-Inflammatory Biologics Market Trends and Growth Analysis 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Anti-Inflammatory Biologics Market Over The Five-Year Period 2025–2029?

The market size for anti-inflammatory biologics has demonstrated robust growth in recent years. Forecasts indicate it will expand from $108.11 billion in 2024 to $118.02 billion in 2025, achieving a compound annual growth rate (CAGR) of 9.2%. Historically, this expansion has been propelled by factors like the increasing prevalence of arthritis, heightened awareness of autoimmune diseases, the continuous introduction of new biologics, advancements in healthcare infrastructure, and an increase in regulatory approvals.

The anti-inflammatory biologics market is projected to experience substantial expansion in the coming years. This market is forecast to reach a size of $166.28 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.0%. The anticipated growth during the forecast period is primarily driven by factors such as the expanding uptake of biologics, a heightened call for targeted therapeutic approaches, patients’ growing inclination towards sustained remission, the rising application of biomarkers for tracking diseases, and an increasing need for personalized medical treatments. Key trends anticipated within this period encompass progress in the development of biologic drugs, the creation of oral biologics specifically for inflammation, innovative technology-led drug delivery systems, significant advancements in biosimilar products, and improvements in diagnostic methodologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Anti-Inflammatory Biologics Industry?

The expanding occurrence of arthritis is anticipated to fuel the future expansion of the anti-inflammatory biologics market. Arthritis is characterized by the inflammation or swelling of one or more joints, leading to discomfort, rigidity, and limited mobility, frequently intensifying with age. This surge in arthritis cases is largely attributed to escalating obesity rates, given that excess body weight puts extra strain on joints, resulting in inflammation and the deterioration of joint tissue. Anti-inflammatory biologics provide benefits for arthritis by targeting particular elements of the immune system to decrease inflammation, inhibit joint damage, alleviate symptoms, and enhance the physical function and overall quality of life for individuals suffering from moderate to severe arthritis. To illustrate, data from March 2023, sourced from the Office for Health Improvement and Disparities, a UK-based government department, revealed that in 2022, 17.6% of individuals aged 16 and above reported a long-term MSK condition like arthritis or a persistent back or joint issue, marking an increase from 17.0% in 2021. Consequently, the increasing incidence of arthritis is stimulating the expansion of the anti-inflammatory biologics market.

Which Key Segments Fueling The Anti-Inflammatory Biologics Market?

The anti-inflammatory biologics market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous

3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:

1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol

2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors

3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab

4) By T-Cell Inhibitors: Abatacept, Alefacept

5) By Other Drug Classes: Janus Kinase Inhibitors, Phosphodiesterase-4 Inhibitors, Sphingosine 1-Phosphate Receptor Modulators, Anti-IgE And Other Biologics

What Key Innovation Trends Are Fueling Advancements In The Anti-Inflammatory Biologics Market?

Leading companies within the anti-inflammatory biologics market are concentrating on creating advanced remedies, such as interleukin-6 (IL-6) receptor antagonists, designed to address chronic inflammatory conditions with enhanced precision and fewer adverse effects. Interleukin-6 (IL-6) receptor antagonists are a class of biologic medications that work by obstructing the IL-6 receptor, thereby mitigating inflammation and immune responses in ailments like rheumatoid arthritis. For example, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology firm, obtained clearance from the US Food and Drug Administration (FDA) for Kevzara, marking it as the initial and sole biologic treatment specifically for patients with polymyalgia rheumatica (PMR) who do not adequately respond to corticosteroids. Kevzara operates as a fully human monoclonal antibody, which inhibits the IL-6 receptor, helping to diminish inflammation associated with PMR, a condition characterized by muscle pain and stiffness, predominantly in older adults. In contrast to conventional steroids, which carry risks such as osteoporosis and diabetes with prolonged usage, Kevzara offers a more directed, steroid-sparing strategy that supports improved patient results and heightened long-term safety.

Which Key Market Players Are Investing In Expansion And Innovation Of Anti-Inflammatory Biologics Market?

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc., Regeneron Pharmaceuticals Inc, Biogen Inc., UCB S.A, UCB S.A./N.V, Swedish Orphan Biovitrum AB, Almirall S.A., Evotec SE, Hansa Biopharma AB.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

Which Region Is Projected To Lead The Anti-Inflammatory Biologics Market During The Forecast Period?

North America was the largest region in the anti-inflammatory biologics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Anti-Inflammatory Biologics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25695&type=smp

Browse Through More Reports Similar to the Global Anti-Inflammatory Biologics Market 2025, By The Business Research Company

Anti Inflammatory Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Non Steroidal Anti Inflammatory Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Rare Inflammatory Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795